[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Roflumilast is a new drug with innovative pharmacodynamic properties for use in patients with chronic obstructive pulmonary disease (COPD). By selective inhibition of phosphodiesterase-4 roflumilast targets inflammatory processes in COPD, with beneficial effects on smoking-induced bronchial inflammation, fibrotic remodeling, mucociliary malfunction and oxidative stress.
Klinik III für Innere Medizin, Universität zu Köln. guido.michels@uk-koeln.de
G
G
Michels
E
E
Erdmann
R
R
Pfister
D000631:Aminopyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000075202:Contraindications; D003521:Cyclopropanes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D009079:Mucociliary Clearance / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D058988:Phosphodiesterase 4 Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012907:Smoking / Q000009:adverse effects
D000631:Aminopyridines; D001549:Benzamides; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D058988:Phosphodiesterase 4 Inhibitors; C424423:Roflumilast